

Putting NICE guidance into practice

Implementing the NICE guidance on the ReCell Spray-On Skin system for treating skin loss, scarring and depigmentation after burn injury (MTG21)

Published: November 2014

The commissioner for this technology is clinical commissioning groups.

More evidence is needed to support the case for routine adoption of the ReCell Spray-On Skin system in the NHS. Research is recommended to address uncertainties about the claimed patient and system benefits of using the technology.

Therefore, at present, no significant costs are anticipated.